Jade Biosciences (JBIO) Q3 2026 earnings summary

Executive summary

• Three clinical-stage programs advanced toward key 2026–2027 milestones, including planned Phase 3 initiation for JADE101 and Phase 1 initiation for JADE301.

• Cash, cash equivalents, and investments totaled $475.7 million at September 30, 2026, with expected runway into Q4 2028.

Financial highlights

• Q3 2026 R&D expense was $30.8 million, up $8.8 million YoY; G&A expense was $8.8 million, up $3.4 million YoY.

• Q3 2026 net loss was $35.0 million, versus $25.2 million in Q3 2025; higher R&D and G&A costs drove the increase.

• 9M 2026 net loss was $131.2 million, versus $95.5 million in 9M 2025.

Outlook and guidance

• JADE101 Phase 3 registrational EVERGREEN trial in IgA nephropathy expected to start in Q4 2026; JADE101 Phase 2 JUNIPER interim data expected Q2 2027.

• JADE201 Phase 1 rheumatoid arthritis interim biomarker-rich data expected in 2027; JADE301 Phase 1 expected to start in Q4 2026, with interim data in H2 2027.

• Existing cash, cash equivalents, and investments expected to fund operating expenses and capital expenditure requirements into Q4 2028, based on current operating plans.